Literature DB >> 8280814

Interstitial lung disease--an underdiagnosed side effect of chlorambucil?

M Mohr1, D Kingreen, H Rühl, D Huhn.   

Abstract

A case of recurrent interstitial pneumonia following re-exposure to chlorambucil therapy for chronic lymphocytic leukemia is presented. Chlorambucil is a rare cause of pulmonary disease. The onset of symptoms may occur after only some weeks or after up to several years with no dose-response relationship. Therapy involves the discontinuation of the offending drug and the administration of steroids. The prognosis is poor, with a mortality greater than 50%.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8280814     DOI: 10.1007/BF01696352

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  14 in total

1.  Busulphan toxicity syndrome caused by chlorambucil.

Authors:  M S Rose
Journal:  Br Med J       Date:  1975-04-19

2.  Interstitial pulmonary fibrosis following busulfan therapy.

Authors:  H OLINER; R SCHWARTZ; F RUBIO; W DAMESHEK
Journal:  Am J Med       Date:  1961-07       Impact factor: 4.965

Review 3.  Chlorambucil lung toxicity.

Authors:  F J Giles; M P Smith; A H Goldstone
Journal:  Acta Haematol       Date:  1990       Impact factor: 2.195

4.  Fatal intraalveolar and interstitial lung fibrosis in chlorambucil-treated chronic lymphocytic leukemia.

Authors:  O Refvem
Journal:  Mt Sinai J Med       Date:  1977 Nov-Dec

Review 5.  The spectrum of drug-induced pulmonary disease.

Authors:  E C Rosenow
Journal:  Ann Intern Med       Date:  1972-12       Impact factor: 25.391

6.  Possible pulmonary effects of alkylating agents.

Authors:  F A Rubio
Journal:  N Engl J Med       Date:  1972-11-30       Impact factor: 91.245

7.  Busulphan lung.

Authors:  W A Littler; J M Kay; P S Hasleton; D Heath
Journal:  Thorax       Date:  1969-11       Impact factor: 9.139

8.  Interstitial pneumonia and chlorambucil.

Authors:  P Godard; J P Marty; F B Michel
Journal:  Chest       Date:  1979-10       Impact factor: 9.410

9.  Pulmonary toxicity recurring after a six week course of busulfan therapy and after subsequent therapy with uracil mustard.

Authors:  D G Hankins; S Sanders; F M MacDonald; C W Drage
Journal:  Chest       Date:  1978-03       Impact factor: 9.410

Review 10.  Pulmonary toxicity of antineoplastic therapy.

Authors:  H Kreisman; N Wolkove
Journal:  Semin Oncol       Date:  1992-10       Impact factor: 4.929

View more
  3 in total

Review 1.  Interstitial lung disease in lung cancer: separating disease progression from treatment effects.

Authors:  Sarah Danson; Fiona Blackhall; Paul Hulse; Malcolm Ranson
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 2.  Anticancer therapy and lung injury: molecular mechanisms.

Authors:  Li Li; Henry Mok; Pavan Jhaveri; Mark D Bonnen; Andrew G Sikora; N Tony Eissa; Ritsuko U Komaki; Yohannes T Ghebre
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-23       Impact factor: 4.512

3.  Chlorambucil-induced acute interstitial pneumonitis.

Authors:  Hammad Shafqat; Adam J Olszewski
Journal:  Case Rep Hematol       Date:  2014-02-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.